Shares in London are down marginally as traders struggle for direction with HSBC grabbing headlines for its profits slump. Click here for The Trader Nicole Elliott's latest thoughts.
IC TIP UPDATES:
If Vernalis (VER) investors will keep fixating on cough and cold medicine Tuzistra, they’re bound to be repeatedly disappointed. Once again the medicine, which was launched in the US in 2015, failed to reach its sales expectations. Vernalis shares are down 11 per cent in early trading as a result. But we are keeping the faith. Vernalis is more than just Tuzistra and its new cough and cold medicines are progressing fast through the pipeline. Buy.